Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study
15 August 2017
Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study
Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced the last patient last visit in the ongoing Phase I/II study of ilixadencel in hepatocellular carcinoma (HCC). The open label study enrolled eighteen patients and was conducted at the Sahlgrenska University Hospital at Gothenburg University. Topline results from the study following data analysis are anticipated before the end of the year. Ilixadencel, formerly known as INTUVAX, is a cancer immune primer developed for the treatment of solid tumors and is currently also being investigated in an ongoing Phase II trial in renal cell carcinoma (MERECA) as well as a Phase I/II study in gastrointestinal stromal tumors.
"Today's announcement continues the significant progress we have made within our clinical programs this year to demonstrate ilixadencel's therapeutic potential as an off-the-shelf immune primer in solid tumors. HCC in particular is a very severe type of cancer with limited treatment options and a strong demand for novel, innovative therapies such as ilixadencel," said Peter Suenaert, MD, PhD, Immunicum's Chief Medical Officer. "Especially in this rapidly advancing type of cancer, the ability to extend survival by even a few months is a positive benefit. The interim results we presented at the SITC Annual meeting last November were promising and we look forward to the complete results, which we hope to communicate before end of year."
The open-label phase I/II trial was initiated by Immunicum in 2013 to investigate safety and efficacy of ilixadencel, Immunicum's lead cancer immune primer, as second and first line therapy in HCC. Conducted at the Sahlgrenska University Hospital at Gothenburg University, the primary objective of the study is to investigate safety of the cell therapy product. Secondary objectives include immunological response and initial signs of efficacy on overall survival. In total, eighteen patients were enrolled in the study, seventeen with advanced HCC and one with bile-duct cancer (following protocol amendment). All patients were treated with at least one intratumoral dose of ilixadencel either as a monotherapy or in combination with first line treatment sorafenib. Interim results presented at the SITC Annual meeting in November 2016 demonstrated a good safety and tolerability profile.
More information on the study can be found on the clinicaltrial.gov page through the following link: https://www.clinicaltrials.gov/ct2/show/NCT01974661?term=Immunicum&rank=3
About hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and the most common cause of death in people with liver cirrhosis. Progression is very rapid and prognosis is poor due to the inability to completely remove the tumor through surgery in most cases. Malignant transformation of liver cells may occur as a consequence of various origins, such as chronic viral hepatitis, alcohol, and metabolic disorders.
Ilixadencel cell therapy product (formerly known as INTUVAX ® ) is an off-the-shelf cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-lymphocytes.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
Investor Relations Sweden
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
Investor and Media Relations EU/US
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
About Immunicum AB (publ)Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Mitratech Acquires ThinkSmart LLC to Create Industry-First, End-to-End Legal Operations Platform23.4.2018 17:00 | Pressmeddelande
Integration of ThinkSmart's agile workflow software into Mitratech's TeamConnect platform sets a new global standard for legal and compliance innovation and excellence LAS VEGAS, April 23, 2018 (GLOBE NEWSWIRE) -- Today, Mitratech a leading provider of legal and compliance software, announced the acquisition of ThinkSmart LLC, creating an end-to-end platform designed to transform legal operations into a center of innovation and excellence. With the addition of ThinkSmart and the ThinkSmart Automation Platform (TAP), Mitratech's TeamConnect platform can now bring people, processes and information together like never before, by leveraging TAP's easy-to-use workflow automation engine to extend TeamConnect's reach across the entire enterprise. In today's rapidly evolving legal landscape, there is a need for a truly evolutionary Enterprise Legal Management (ELM) platform. ELM systems have delivered on the operational efficiencies, centralized view of information, security and data integrity
Vricon unveils new solution at GEOINT 2018: Vricon Precision 3D Registration (P3DR)23.4.2018 16:20 | Pressmeddelande
Precise, accurate, georegistered GEOINT data for analytics and visualization-at a global scale McLean, Virginia, April 23, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that it is unveiling the next in a series of GEOINT solutions - Vricon Precision 3D Registration (P3DR) - at this year's GEOINT 2018 Symposiumin Tampa, Fla. Vricon P3DR is a software suite designed to automatically georegister imagery, regardless of collection platform, against the most accurate 3D geospatial foundation available, The Globe in 3D. P3DR can be implemented as a real-time processing workflow for imagery feeds without the need for GPS location, heading information, or ground control points. "While we've always been able to perform georegistration of individual data sets using our 3D models as an accurate foundation, Vricon P3DR takes this capability to a whole new level," said Magnus Brege, Vricon CEO. "Our users now have multiple options for where and when they can automatically georegister their
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA23.4.2018 14:15 | Pressmeddelande
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, the Company's AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease. "We are encouraged to have received the first gene therapy RMAT designation in MPS IIIA and look forward to further collaborating with the FDA to determine next steps in the development pathway for ABO-102," said Carsten Thiel, Ph.D., CEO of Abeona Therapeutics. "This action further reinforces the clinical significance in the data observed in the ongoing P
Gratomic and Perpetuus Carbon Technologies Limited Enter Into an Agreement for the Exclusive Development and Marketing of Material Enhancing Graphenes Derived From Gratomic Aukam Graphite23.4.2018 14:00 | Pressmeddelande
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A2JAP3). Gratomic Inc., is pleased to announce that the Company has signed a letter of collaboration ("Agreement") with Perpetuus Carbon Technologies Limited ("Perpetuus") pursuant to which GRAT and Perpetuus will develop and market material enhancing graphite derived graphenes and graphene hybrids for tire elastomers, whilst also exploring options to exploit polymer composites, energy capture and storage applications markets ("Project"). The Agreement contemplates the first Phase of the Project ("Phase 1"), with the other phases to be described in a joint venture agreement to be entered into between GRAT and Perpetuus. Pursuant to the Agreement, and as part of Phase 1, GRAT will purchase, and retain ownership, of three specialised process tooling chambers at an aggregate cost of 300,000 British Pounds. These specialized tooling chambers will be housed in Perpetuus' ex
BIMobject AB: BIMobject signs Letter of Intent with leading US 3D media company Matterport23.4.2018 08:30 | Pressmeddelande
PRESS RELEASE Malmö, Sweden 2018-04-23 BIMobject signs Letter of Intent with leading US 3D media company Matterport BIMobject, who digitalizes the construction industry through cloud-based platforms and other solutions, has signed a Letter of Intent with Matterport, a leading 3D immersive media technology company. The purpose is to integrate the companies' platforms and create user-friendly solutions. This will allow for the easy use of digital building and interior products from BIMobject Cloud, such as sofas and windows, in Matterport's 3D spaces. The integrations will enable detailed visualization in Virtual Reality and other technologies. California-based Matterport offers a leading 3D reality capture system and platform that can be used to map out surroundings, such as entire homes or buildings. The system produces multiple outputs including immersive 3D environments that can be experienced on desktop computers, mobile devices, and Virtual Reality headsets as well as high-resoluti
BIMobject AB: BIMobject tecknar avsiktsförklaring med det ledande amerikanska 3D-mediebolaget Matterport23.4.2018 08:30 | Pressmeddelande
PRESSMEDDELANDE Malmö, Sverige 2018-04-23 BIMobject tecknar avsiktsförklaring med det ledande amerikanska 3D-mediebolaget Matterport BIMobject, som digitaliserar byggbranschen bland annat via molnbaserade plattformar, och Matterport, ett ledande 3D-medieteknikbolag, har tecknat en avsiktsförklaring. Syftet är att integrera bolagens plattformar och skapa användarvänligare lösningar. Virtuella bygg- och inredningsprodukter som nedladdas från BIMobject, exempelvis soffor eller fönster, ska enkelt kunna användas i Matterports 3D-skannade miljöer, vilket möjliggör för en detaljrik visualisering via exempelvis Virtual Reality. Kalifornien-baserade Matterport erbjuder system och plattformar för 3D-skanning som kan användas för att kartlägga omgivningar såsom hela rum eller byggnader. Systemet möjliggör att de inskannade omgivningarna kan användas som högupplösta fotografier, 3D-modeller, planlösningar eller användas som 3D-miljöer tillsammans med Virtual Reality-glasögon (VR), en vanlig dator
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum